Haleh Vaziri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haleh Vaziri has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Aksenov
University of Connecticut
41 shared publications - Ali Lotfi
Department of Chemistry, University of Connecticut
41 shared publications - Anthony Athanasios Provatas
University of Connecticut Center for Environmental Science and Engineering, Storrs, USA
41 shared publications - Daniel W. Rosenberg
Centre for Molecular Oncology, Carole and Ray Neag Comprehensive Cancer Center, School of Medicine, University of Connecticut Health, Farmington, USA
41 shared publications - James J. Grady
Department of Public Health Sciences, UConn Health, Farmington, Connecticut, USA
41 shared publications - John Birk
Division of Gastroenterology, University of Connecticut, Farmington, Connecticut
41 shared publications
Latest Publications
- 18 August 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-13
Chronotherapy in Inflammatory Bowel Disease: Biological Rationale, Human Evidence, and a Clinical Implementation Framework
Inflammatory bowel disease (IBD) is a chronic condition driven by a dysregulated immune response to the gut microbiome in genetically susceptible individuals. This process may be influenced by the circadian rhythm, the body’s internal 24-h clock that coordinates physiology with the day–night cycle. Disruption of this rhythm, whether from behavior or intrinsic dysfunction, can disturb intestinal homeostasis and promote inflammation. Chronotherapy applies this concept clinically by aligning medical treatment with circadian timing to optimize efficacy and reduce adverse effects. There is growing evidence suggesting the importance of this approach for drug metabolism, immune activity, and symptom patterns, offering a new dimension of personalization beyond medication choice alone. This review summarizes the biological links between circadian regulation and intestinal inflammation, highlights emerging human data supporting time-based treatment strategies, and proposes a practical framework for integrating chronotherapy into routine IBD management. By considering when a therapy is delivered in addition to what therapy should be used, clinicians may enhance treatment response, limit toxicity, and improve overall disease control.
- 18 August 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-13
Chronotherapy in Inflammatory Bowel Disease: Biological Rationale, Human Evidence, and a Clinical Implementation Framework
Inflammatory bowel disease (IBD) is a chronic condition driven by a dysregulated immune response to the gut microbiome in genetically susceptible individuals. This process may be influenced by the circadian rhythm, the body’s internal 24-h clock that coordinates physiology with the day–night cycle. Disruption of this rhythm, whether from behavior or intrinsic dysfunction, can disturb intestinal homeostasis and promote inflammation. Chronotherapy applies this concept clinically by aligning medical treatment with circadian timing to optimize efficacy and reduce adverse effects. There is growing evidence suggesting the importance of this approach for drug metabolism, immune activity, and symptom patterns, offering a new dimension of personalization beyond medication choice alone. This review summarizes the biological links between circadian regulation and intestinal inflammation, highlights emerging human data supporting time-based treatment strategies, and proposes a practical framework for integrating chronotherapy into routine IBD management. By considering when a therapy is delivered in addition to what therapy should be used, clinicians may enhance treatment response, limit toxicity, and improve overall disease control.
- 27 June 2026
- Published by SAGE Publications in American Journal of Lifestyle Medicine
Environmental and Lifestyle Factors in Inflammatory Bowel Diseases
Inflammatory bowel disease (IBD) is a chronic, multifactorial disease resulting from complex interactions between the immune system, gut microbiota, genetic susceptibility, and environmental factors. Although advances in pharmacologic therapies have improved disease control, increasing evidence indicates that lifestyle and environmental factors influence disease course and patient well-being. In this review, we assess the impact of lifestyle factors (diet, physical activity, sleep, mental health, and smoking) and environmental factors (pesticides, microplastics, and heavy metals) on IBD. Our manuscript highlights the importance of minimizing highly processed foods, such as those in the Western diet, while promoting a whole-food and Mediterranean diets, regular physical activity, and monitoring for micronutrient deficiencies. We also provide information on sleep disturbances, mental health, and disease activity, as well as interventions such as cognitive-behavioral therapy and mindfulness, which may improve the quality of life of these patients. Emerging evidence suggests that environmental pollutants, including microplastics and pesticides, may affect IBD risk and progression, highlighting the need for further research. Integrating structured lifestyle recommendations into clinical care may have a significant role in improving outcomes in patients with IBD.
- 27 June 2026
- Published by SAGE Publications in American Journal of Lifestyle Medicine
Environmental and Lifestyle Factors in Inflammatory Bowel Diseases
Inflammatory bowel disease (IBD) is a chronic, multifactorial disease resulting from complex interactions between the immune system, gut microbiota, genetic susceptibility, and environmental factors. Although advances in pharmacologic therapies have improved disease control, increasing evidence indicates that lifestyle and environmental factors influence disease course and patient well-being. In this review, we assess the impact of lifestyle factors (diet, physical activity, sleep, mental health, and smoking) and environmental factors (pesticides, microplastics, and heavy metals) on IBD. Our manuscript highlights the importance of minimizing highly processed foods, such as those in the Western diet, while promoting a whole-food and Mediterranean diets, regular physical activity, and monitoring for micronutrient deficiencies. We also provide information on sleep disturbances, mental health, and disease activity, as well as interventions such as cognitive-behavioral therapy and mindfulness, which may improve the quality of life of these patients. Emerging evidence suggests that environmental pollutants, including microplastics and pesticides, may affect IBD risk and progression, highlighting the need for further research. Integrating structured lifestyle recommendations into clinical care may have a significant role in improving outcomes in patients with IBD.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S8: Baseline sociodemographic characteristics of 38 study participants based on urinary urolithin A production
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S8: Baseline sociodemographic characteristics of 38 study participants based on urinary urolithin A production
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Figure S2: Polyp tissues used for IMC analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Figure S2: Polyp tissues used for IMC analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S3: List of serum markers analyzed in the patients
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S3: List of serum markers analyzed in the patients
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S6: Urinary urolithin metabolomic data after enzymatic hydrolysis, as described under Materials and methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S6: Urinary urolithin metabolomic data after enzymatic hydrolysis, as described under Materials and methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S9: Non-hydrolyzed fecal urolithin A levels
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S9: Non-hydrolyzed fecal urolithin A levels
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Figure S1: Selection of study participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Figure S1: Selection of study participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S10: Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S10: Representativeness of Study Participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S1: List of food items study participants were asked to avoid during the 7-day washout period and 3-week walnut supplementation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Systemic Inflammation and the Inflammatory Context of the Colonic Microenvironment Are Improved by Urolithin A
Supplementary Table S1: List of food items study participants were asked to avoid during the 7-day washout period and 3-week walnut supplementation.